Back to results
US 2022/0064169 A1Published application
Novel compounds
AssigneeIntra-Cellular Therapies, Inc.
InventorsPeng LI, Hailin ZHENG
Life of this patent
Estimating the term…
Abstract
The present disclosure relates to novel PDE2 inhibitory compounds of Formula I as described herein, their use as pharmaceuticals and pharmaceutical compositions comprising them.
Claims17
A Compound of Formula I
- wherein
- (i) R1 and R2 together with the nitrogen atom form a heteroC3-7cycloalkyl (e.g., forms an azetidin-1-yl);
- (ii) R3 is H or C1-4alkyl (e.g., methyl);
- (iii) R4 is heteroaryl, halo (e.g. chloro), cyano or aryl (e.g., phenyl) optionally substituted with one or more groups selected from C1-4alkyl (e.g., methyl, ethyl, or propyl, e.g., isopropyl), C3-7cycloalkyl (e.g., cyclopropyl), C1-4alkoxy (e.g., methoxy) and haloC1-4alkyl (e.g., trifluoromethyl);
- (iv) R5 is H or C1-4alkyl (e.g., methyl);
- (v) R6 is H or C1-4alkyl (e.g., methyl).
- in free or salt form.
4 more elements
Any of the preceding Formulae, wherein the compound is selected from a group consisting of:
- 8-(azetidin-1-yl)-3-methyl-1-(1-methyl-5-(p-tolyl)-1H-pyrazol-4-yl)imidazo[1,5-a]pyrazine,
- 8-(azetidin-1-yl)-3-methyl-1-(1-methyl-5-(4-(trifluoromethyl)phenyl)-1H-pyrazol-4-yl)imidazo[1,5-a]pyrazine,
- 8-(azetidin-1-yl)-3,5-dimethyl-1-(1-methyl-5-(4-(trifluoromethyl)phenyl)-1H-pyrazol-4-yl)imidazo[1,5-a]pyrazine,
- 8-(azetidin-1-yl)-1-(5-(4-isopropylphenyl)-1-methyl-1H-pyrazol-4-yl)-3-methyl-imidazo[1,5-a]pyrazine,
- 8-(azetidin-1-yl)-1-(5-(4-ethylphenyl)-1-methyl-1H-pyrazol-4-yl)-3-methylimidazo[1,5-a]pyrazine,
- 8-(azetidin-1-yl)-1-(5-(4-cyclopropylphenyl)-1-methyl-1H-pyrazol-4-yl)-3-methyl-imidazo[1,5-a]pyrazine;
- in free or salt form.
4 more elements
(canceled)
(canceled)
(canceled)
Dependencies are inferred from the claim text.